Skip to main content

Advertisement

Table 2 Subgroup analysis for the main potential confounding factors with random effects model

From: Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer

Subgroup Number of study OR 95% CI Q I2 P-value
Overall 18 4.67 2.65 to 8.21 73.99 77.00%  
Age ≤ 65 9 5.03 2.53 to 10.0 27.96 71.40%  
Age > 65 3 0.91 0.57 to 1.41 2.21 9.400% < 0.0001
Stage I > 49.5% 5 4.11 1.90 to 8.91 12.76 68.60%  
Stage I ≤ 49.5% 4 2.81 0.87 to 9.09 19.42 84.60% 0.5944
M2F ≤ 69% 6 5.98 2.04 to 17.53 16.66 70.00%  
M2F > 69% 6 2.13 0.99 to 4.55 29.05 82.80% 0.1246
MSP 8 5.16 2.01 to 13.26 44.61 84.30%  
qMSP 10 4.32 2.08 to 8.94 29.28 69.30% 0.7685
Diagnose 13 6.79 2.99 to 15.44 59.54 79.80%  
Non-diagnose 5 2.59 1.33 to 5.05 11.56 65.40% 0.0745
Multiple targets 15 4.08 2.28 to 7.34 62.99 77.80%  
Single target 3 18.72 1.23 to 283 9.03 77.80% 0.2836
Heterogeneous 12 8.33 3.77 to 18.39 35.71 69.20%  
Autogenous 6 2.25 1.06 to 4.77 27.19 81.60% 0.0187
Serum 5 11.54 2.87 to 46.40 10.4 61.50%  
Tissue 13 3.72 2.03 to 6.78 55.18 78.30% 0.14
Ad2Sc < 2 9 2.46 1.35 to 4.48 35.79 77.00%  
Ad2Sc > = 2 2 17.1 4.68 to 62.7 0.11 0.000% 0.0077
Primer set I 5 5.41 2.43 to 12.04 13.71 70.80%  
Primer set II 4 1.82 1.05 to 3.13 4.57 34.30% 0.0137 a
  1. Bold P-values lower than 0.05 indicate significant differences between groups (random effects model, d.f. = 1).
  2. aThe serum groups and the studies with less than 50 samples were removed.